It spells a payday for Melbourne’s Viridian Advisory, which shot to prominence six years ago when it acquired Westpac’s ...

Viridian has agreed to a strategic investment for an undisclosed amount from private equity firm TA Associates.

Viridian manages around $16bn in funds across Viridian Advisory, Infinity Capital Solutions, Smartmove Lending.

TA Associates announced it will make an undisclosed investment in Viridian Financial Group to help the latter accelerate its next phase of growth.

Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, ...

Viridian Therapeutics (NASDAQ:VRDN) reported positive topline results from the THRIVE-2 phase 3 trial of veligrotug (VRDN-001) in chronic thyroid eye disease (‘TED’) patients.

Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase 3 clinical trial of veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor antibody, in ...

Viridian Therapeutics' experimental treatment for chronic thyroid eye disease (TED) significantly reduced symptoms such as double vision and eye bulging in a late-stage study, sending its shares ...

Viridian commonly uses Discounted Cash Flow Analysis, Public Company Comparables, and M&A Precedent Transactions to value both small private concerns as well as larger public companies.